THE CAMZYOS (MAVACAMTEN) RISK EVALUATION AND MITIGATION STRATEGY PROGRAM: RESULTS FROM 10 MONTHS POST-LAUNCH

被引：0
|
作者：
Martinez, Matthew W.
Ferri, Leticia
Patel, Niki
Minton, Neil
Lockman, Jeffrey
Cheung, Michael
Coiro, Michele
Afsari, Sonia
Seto, Dewey
机构：
[1] Atlantic Hlth Syst, Morristown Med Ctr, Dept Med, Morristown, NJ USA
[2] Bristol Myers Squibb, Princeton, NJ USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2024年 / 83卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1075-07
引用
收藏
页码：354 / 354
页数：1
相关论文
共 50 条
  • [1] Mavacamten: Real-World Experience From 22 Months of the Risk Evaluation and Mitigation Strategy (REMS) Program
    Desai, Milind Y.
    Seto, Dewey
    Cheung, Michael
    Afsari, Sonia
    Patel, Niki
    Bastien, Arnaud
    Lockman, Jeffrey
    Coiro, Michele
    Martinez, Matthew W.
    CIRCULATION-HEART FAILURE, 2025, 18 (01)
  • [2] Risk evaluation and mitigation strategy for mavacamten: An example demonstrating appropriate safety oversight
    Desai, Milind Y.
    Nissen, Steve E.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2024,
  • [3] Safety evaluation of phytosterol-esters. Part 9: Results of a European post-launch monitoring programme
    Lea, L. J.
    Hepburn, P. A.
    FOOD AND CHEMICAL TOXICOLOGY, 2006, 44 (08) : 1213 - 1222
  • [4] The Xyrem® (Sodium Oxybate) Risk Evaluation and Mitigation Strategy (REMS) Program in the USA: Results From 2016 to 2017
    Strunc, Michael J.
    Black, Jed
    Lillaney, Prasheel
    Profant, Judi
    Mills, Sherice
    Bujanover, Shay
    Thorpy, Michael J.
    DRUGS-REAL WORLD OUTCOMES, 2021, 8 (01) : 15 - 28
  • [5] The Xyrem® (Sodium Oxybate) Risk Evaluation and Mitigation Strategy (REMS) Program in the USA: Results From 2016 to 2017
    Michael J. Strunc
    Jed Black
    Prasheel Lillaney
    Judi Profant
    Sherice Mills
    Shay Bujanover
    Michael J. Thorpy
    Drugs - Real World Outcomes, 2021, 8 : 15 - 28
  • [6] CLOZAPINE AND AGRANULOCYTOSIS: IMPACT OF THE RISK EVALUATION AND MITIGATION STRATEGY PROGRAM
    Borrelli, E. P.
    Lee, E. Y.
    Descoteaux, A. M.
    Caffrey, A. R.
    VALUE IN HEALTH, 2018, 21 : S180 - S180
  • [7] Assessing the Opioid Analgesic Risk Evaluation and Mitigation Strategy Program
    Auth, Doris
    Staffa, Judy
    LaCivita, Cynthia
    JAMA INTERNAL MEDICINE, 2020, 180 (06) : 915 - 916
  • [8] Results from a post-launch monitoring survey on consumer purchases of foods with added phytosterols in five European countries
    Willems, Julie I.
    Blommaert, Mireille A. E.
    Trautwein, Elke A.
    FOOD AND CHEMICAL TOXICOLOGY, 2013, 62 : 48 - 53
  • [9] Assessing the Opioid Analgesic Risk Evaluation and Mitigation Strategy Program Reply
    Heyward, James
    Sharfstein, Joshua
    Alexander, G. Caleb
    JAMA INTERNAL MEDICINE, 2020, 180 (06) : 916 - 916
  • [10] Sodium oxybate post-marketing evaluation program: Results from the first 12 months
    Ritzinger, CA
    Nelson, JA
    SLEEP, 2004, 27 : 247 - 247
12345